A normal fasting plasma glucose is less than 100 mg/dL. A blood glucose greater than 100 mg/dL is referred to as hyperglycemia. A patient has impaired glucose tolerance, or pre-diabetes, with a fasting plasma glucose of 100 mg/dL to 125 mg/dL. A patient is termed diabetic with a fasting blood glucose of greater than 125 mg/dL.
When hyperglycemia is left untreated, it can lead to many serious limb and life-threatening complications that include damage to the eye, kidneys, nerves, heart, and the peripheral vascular system. Thus, it is vital to refer patients to the different specialists to obtain a baseline screening exam early on.
Factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production. Glucose homeostasis is a balance between hepatic glucose production and peripheral glucose uptake and utilization. Insulin is the most important regulator of glucose homeostasis.
Secondary cause of hyperglycemia include the following:
Major risk factors for hyperglycemia:
The incidence of hyperglycemia has increased dramatically over the last two decades due to increased obesity, decreased activity level, and an aging population. The prevalence is equal between men and women. The countries with the greatest number of diabetics included China, India, United States, Brazil, and Russia. Hyperglycemia is more prominent in low to medium income households.
The latest data released by the Centers for Disease Control and Prevention indicate that there are nearly 30.5 million Americans with diabetes and nearly 84 million Americans with prediabetes. These numbers are set to increase significantly over the next decade.
Hyperglycemia in a patient with type 1 diabetes is a result of genetic, environmental, and immunologic factors. These lead to the destruction of pancreatic beta cells and insulin deficiency. In a patient with type 2 diabetes, insulin resistance and abnormal insulin secretion lead to hyperglycemia.
The early symptoms of hyperglycemia include polyuria, polydipsia, and weight loss. As the patient's blood glucose increases, neurologic symptoms can develop. The patient may experience lethargy, focal neurologic deficits, or altered mental status. The patient can progress to a comatose state.
Patients with diabetic ketoacidosis may present with nausea, vomiting and abdominal pain. They also may have a fruity odor and deep respirations, reflecting the compensatory hyperventilation.
When evaluating a patient for hyperglycemia, the focus should be on the patient's cardiorespiratory status, mental status, and volume status. A bedside serum glucose can be obtained quickly. Testing includes serum electrolytes with the calculation of the anion gap, BUN and creatinine, and complete blood count. Urinalysis by dipstick assesses for glucose and ketones in the urine. Arterial blood gas or venous blood gas may be necessary if serum bicarbonate is substantially reduced.
Blood Glucose Determination
To determine if the patient has developed type 2 diabetes the patient needs to have the following outcomes on these tests:
A fasting plasma glucose level of 126 mg/dL or higher.
A 2-hour plasma glucose level of 200 mg/dL or higher during a 75-g oral glucose tolerance test (OGTT).
A random plasma glucose of 200 mg/dL or higher in the presence of symptoms of hyperglycemia.
A hemoglobin A1c level of 6.5% or higher.
The treatment goals of hyperglycemia involve eliminating the symptoms related to hyperglycemia and reducing the long-term complications. Glycemic control in patients with type 1 diabetes is achieved by variable insulin regimen along with proper nutrition. Patients with type 2 diabetes are managed with diet and lifestyle changes as well as medications. Type 2 diabetes also may be managed on oral glucose-lowering agents. Patients with hyperglycemia need to be screened for complications including retinopathy, nephropathy, and cardiovascular disease.
Goals of Treatment
Treatment goals are to reduce the the following complications associated with hyperglycemia:
Patients who have hyperglycemia and are confirmed to have type 2 diabetes need to be referred to an endocrinologist. Unless there is a contraindication, the drug of first choice to lower hyperglycemia is metformin. In addition, some patients may require insulin therapy in combination with other agents.
Prevention of complications
To prevent complications of hyperglycemia, the following preventive approaches are recommended:
The prognosis of individuals with hyperglycemia depends on how well the levels of blood glucose are controlled. Chronic hyperglycemia can cause severe life- and limb-threatening complications. Changes in lifestyle, regular physical exercise, and changes in diet are the keys to a better prognosis. Individuals who maintain euglycemia have a markedly better prognosis and an improved quality of life compared to individuals who remain hyperglycemic. Once the complications of hyperglycemia have developed, they are basically irreversible. Countless studies have shown that untreated hyperglycemia shortens lifespan and worsens the quality of life. Thus, aggressive lowering of hyperglycemia must be initiated, and patients must be closely followed. Studies suggest that one should try to achieve an A1C level of less than 7%. However, controlling blood sugars too tightly can result in hypoglycemia which is not well tolerated by elderly individuals who already may have a pre-existing cardiovascular disease.
Patients with severe hyperglycemia should be assessed for clinical stability including mentation and hydration. Diabetic ketoacidosis and hyperglycemic hyperosmolar state are acute, severe disorders related to hyperglycemia.
Patients confirmed with type 2 diabetes are faced with a life-long challenge to maintain euglycemia. This is not an easy undertaking and is also prohibitively expensive. Patients must be educated that making changes in their lifestyle can markedly improve their prognosis.